PT-141
Bremelanotide, Vyleesi
REC PPT-PT-141 // REV 2026-10-04 // assessment changes are logged, never silent
Approved as bremelanotide for HSDD in premenopausal women.
What it is
A melanocortin receptor agonist approved under the name bremelanotide (Vyleesi).
What it does
Acts centrally on melanocortin pathways rather than on vascular mechanisms like PDE5 inhibitors.
Does it work?
Has genuine regulatory approval and trial data for a specific indication in women. Nausea and flushing are commonly reported. Off-label use in men is far less well characterised.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Approved for low sexual desire in premenopausal women | supported |
| Nausea is a common side effect | supported |
| Works like PDE5 drugs such as sildenafil | overreach |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
molecular data — PubChem CID 9941379
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
112 publications indexed, but only 6 randomised controlled trials and 4 registered interventional studies. Human evidence exists but is thin.
SRC // EUROPE PMC + CTGOV // "PT-141" // FETCHED 2026-10-04 // 112 RECORDS
Most-cited literature
-
[01]
The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology
Tao YX. · Endocr Rev 2010 · 421 citations · DOI 10.1210/er.2009-0037
-
[02]
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu B, Li S, Shi R, Liu H. · Signal Transduct Target Ther 2023 · 259 citations · DOI 10.1038/s41392-023-01654-7
-
[03]
Anion-Exchange Membrane Water Electrolyzers
Du N, Roy C, Peach R, Turnbull M, Thiele S, Bock C. · Chem Rev 2022 · 250 citations · DOI 10.1021/acs.chemrev.1c00854
-
[04]
Photons or Electrons? A Critical Comparison of Electrochemistry and Photoredox Catalysis for Organic Synthesis
Tay NES, Lehnherr D, Rovis T. · Chem Rev 2022 · 234 citations · DOI 10.1021/acs.chemrev.1c00384
Regulatory status
Formal, dated regulatory actions.
Common questions
What is PT-141 approved for exactly?
As bremelanotide (Vyleesi) for acquired, generalised hypoactive sexual desire disorder in premenopausal women — a defined indication with trial data.
Does it work for men?
Off-label male use is far less characterised. Early erectile-dysfunction development was discontinued, partly over blood-pressure effects.
How does it differ from sildenafil-type drugs?
Completely different mechanism — it acts centrally on melanocortin pathways affecting desire, not on penile blood flow. It is not a PDE5 inhibitor.
Related compounds
Melanotan I
Melanocortin agonist; the regulated version (afamelanotide) is approved for a rare condition.
Kisspeptin-10
Key reproductive-axis regulator with real academic research behind it.
Oxytocin
Approved hormone for obstetric use; social/behavioural claims are far weaker.